Aerie Pharmaceuticals Inc financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
4301 Emperor Boulevard, Suite 400, Durham, North Carolina
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 4, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 261 % -7.06%
Quick Ratio 35.4 % +29.1%
Debt-to-equity -454 % +71.4%
Return On Equity 32.6 % -95.2%
Return On Assets -9.21 % +79.6%
Operating Margin -12.5 % +90.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.4M shares +4.35%
Common Stock, Shares, Outstanding 49.4M shares +4.69%
Common Stock, Value, Issued 49K USD +4.26%
Weighted Average Number of Shares Outstanding, Basic 47.8M shares +3.19%
Weighted Average Number of Shares Outstanding, Diluted 47.8M shares +3.19%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 214M USD +105%
Research and Development Expense 87.6M USD +18.8%
Costs and Expenses 241M USD +1.18%
Operating Income (Loss) -26.7M USD +80%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -35.2M USD +78.1%
Income Tax Expense (Benefit) 1.32M USD -75.5%
Net Income (Loss) Attributable to Parent -36.6M USD +78%
Earnings Per Share, Basic -0.73 USD/shares +34.9%
Earnings Per Share, Diluted -0.73 USD/shares +34.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 54.1M USD -12.5%
Cash, Cash Equivalents, and Short-term Investments 172M USD +2.9%
Accounts Receivable, after Allowance for Credit Loss, Current 73.9M USD +14.4%
Inventory, Net 46.8M USD +55.6%
Assets, Current 303M USD +9.73%
Property, Plant and Equipment, Net 50.3M USD -2.68%
Operating Lease, Right-of-Use Asset 20.8M USD -10.4%
Other Assets, Noncurrent 1.72M USD +72.4%
Assets 376M USD +6.76%
Accounts Payable, Current 9.06M USD +12.2%
Employee-related Liabilities, Current 11.7M USD -19.5%
Accrued Liabilities, Current 119M USD +12.5%
Contract with Customer, Liability, Current 85.5M USD +7.15%
Liabilities, Current 133M USD +12.9%
Contract with Customer, Liability, Noncurrent 70.9M USD +32%
Operating Lease, Liability, Noncurrent 19.5M USD -13.2%
Other Liabilities, Noncurrent 3.25M USD +49.9%
Liabilities 540M USD +27.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -803K USD -1261%
Retained Earnings (Accumulated Deficit) -1.19B USD +0.95%
Stockholders' Equity Attributable to Parent -164M USD -125%
Liabilities and Equity 376M USD +6.76%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 61.9M USD
Net Cash Provided by (Used in) Financing Activities -357K USD +67.6%
Net Cash Provided by (Used in) Investing Activities -42.3M USD -1955%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 49.4M shares +4.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 19.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 54.1M USD -12.5%
Depreciation 1.6M USD +7.01%
Payments to Acquire Property, Plant, and Equipment 1.6M USD +107%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.3M USD +77.6%
Property, Plant and Equipment, Gross 78M USD +6.93%
Operating Lease, Liability, Current 4.87M USD +23.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Additional Paid in Capital 1.02B USD -9.03%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 18.4M USD -44.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%